# Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

> **NCT04775706** · PHASE2 · RECRUITING · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 18 (estimated)

## Conditions studied

- Short Bowel Syndrome

## Interventions

- **DRUG:** HM15912 Active
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04775706
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-03
- **Primary completion:** 2027-12
- **Final completion:** 2028-05
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04775706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04775706, "Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04775706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*